In a report released today, Stephanie Davis from Barclays maintained a Buy rating on Progyny (PGNY – Research Report), with a price target of $30.00. The company’s shares closed last Friday at $28.09.
According to TipRanks, Davis is an analyst with an average return of -6.8% and a 40.65% success rate. Davis covers the Healthcare sector, focusing on stocks such as OptimizeRx, Progyny, and GoodRx Holdings.
Currently, the analyst consensus on Progyny is a Strong Buy with an average price target of $37.75, a 34.39% upside from current levels. In a report released on May 17, Truist Financial also maintained a Buy rating on the stock with a $37.00 price target.
Based on Progyny’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $269.94 million and a net profit of $13.47 million. In comparison, last year the company earned a revenue of $214.32 million and had a net profit of $3.41 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Progyny (PGNY) Company Description:
Progyny, Inc. is a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools. Its services include egg freezing, IVF treatment, surrogacy, podcast, adoption, and Eeva Test. The company was founded on April 03, 2008 and is headquartered in New York, NY.
Read More on PGNY:
- Progyny price target lowered to $37 from $46 at Truist
- Progyny price target lowered to $41 from $51 at JPMorgan
- Progyny, Inc. to Present at BofA Securities 2024 Healthcare Conference and Leerink Partners Healthcare Crossroads Conference 2024
- Progyny price target lowered to $30 from $48 at Barclays
- Progyny price target lowered to $37 from $46 at BofA
